Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Spondyloarthritis

Spondyloarthritis

Part of Arthritis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Spondyloarthritis

8 trials tracked for Spondyloarthritis: 7 in phase 3 or 4 and 6 with published results. The most-cited published study has 17 citations.

8Trials tracked
7Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 2 Phase 3 5 Other / NA 1
  1. Phase 3 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis Completed · 17 cited
  2. Phase 3 A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Completed · 14 cited
  3. Phase 4 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) Completed · 10 cited
  4. Phase 3 SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis Completed · 8 cited
  5. Phase 3 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Completed · 7 cited
  6. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis Completed · 5 cited
Show 2 more trials
  1. Phase 4 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed
  2. N/A Imaging Biomarkers in Crohn's Associated Spondyloarthritis Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Spondyloarthritis: what the trials found

Several biologics and targeted synthetic DMARDs have demonstrated efficacy in treating spondyloarthritis. Ixekizumab showed significant improvements in clinical outcomes, with participants achieving ASAS40 responses (up to 51.8% in some cohorts) and ASAS20 responses ranging from 29.8% to 68.7% [4, 6]. Specifically, Ixekizumab demonstrated significant reductions in Ankylosing Spondylitis Disease Activity Score (ASDAS) compared to baseline [4, 6] and showed high rates of ASAS20 response in bDMARD-naïve patients 7.

Upadacitinib demonstrated statistically significant improvements in disease activity at week 14, with ASAS40 response rates reaching up to 44.9% and substantial reductions in ASDAS scores compared to baseline 3. Golimumab was associated with high percentages of participants remaining without a disease activity flare during Period 2 (up to 84.1%) and showed high clinical response rates following open-label retreatment for those who experienced flares 1.

Other interventions showed specific improvements in pain and index scores. AIN457 demonstrated significant results in reducing spinal pain (NRS score below 4) and improving Bath Ankylosing Spondylitis Disease Activity Index scores at week 8 5. Additionally, Adalimumab was associated with a reduction in the Lewis Score Index 2.

Recent results — preliminary, needs further review

  • Crohn's Disease Activity (Harvey Bradshaw Index (HBI) Score) results were observed in a small cohort without intervention, but these findings are not yet corroborated 8.

For the clinician treating this condition

  • Ixekizumab is associated with significant improvements in both ASAS20 and ASAS40 metrics across multiple study populations [4, 6, 7].
  • Upadacitinib shows statistically significant reductions in ASDAS scores and high rates of ASAS40 response at week 14 3.
  • Golimumab demonstrates high efficacy in preventing disease flares and achieving clinical responses during retreatment 1.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseases
Rheumatology Meta-analysis
FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseases New research maps potential targets for several autoimmune diseases
This evidence-informed review synthesizes the role of FGF/FGFR signaling in conditions including Rheumatoid Arthritis, SLE, and SSc-ILD. The…
Researchers are mapping out how specific proteins might help manage conditions like rheumatoid arthritis and lupus by targeting tissue repai…
Frontiers Jul 24, 2026
Narrative review on multi-omics for spondyloarthritis and psoriatic arthritis
Rheumatology Sys. Review
Narrative review on multi-omics for spondyloarthritis and psoriatic arthritis New multi-omics strategies help doctors better understand spondyloarthritis and psoriatic arthritis conditions
This narrative review synthesizes evidence on multi-omics strategies for spondyloarthritis and psoriatic arthritis. It argues that integrati…
Doctors are using advanced genetic and protein tests to study spondyloarthritis and psoriatic arthritis. These new methods help find better …
Frontiers May 12, 2026

Research across Arthritis

Related studies from across the Arthritis family.

Axia smartphone application increases ASAS20 response to 51% in patients with axial spondyloarthritis
Rheumatology RCT
Axia smartphone application increases ASAS20 response to 51% in patients with axial spondyloarthritis Smartphone app improves quality of life for axial spondyloarthritis
This randomized controlled trial of 186 patients with axial spondyloarthritis found that the Axia app significantly improved BASDAI scores a…
A new smartphone app combining exercise and education helps patients with axial spondyloarthritis manage symptoms and improve daily function…
Aug 5, 2026
Targeting metabolic checkpoints and mechanotransduction may address structural deterioration in axial spondyloarthritis
Allergy & Immunology Sys. Review
Targeting metabolic checkpoints and mechanotransduction may address structural deterioration in axial spondyloarthritis New research identifies why current treatments fail to stop spinal damage
This narrative review explores the limitations of current anti-inflammatory therapies for axial spondyloarthritis and intervertebral disc de…
Current medications may only mask inflammation while structural damage continues. New research points toward targeting the underlying enviro…
Frontiers Jun 30, 2026
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis
Rheumatology RCT
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis Personalized exercise therapy shows promise for axial spondyloarthritis patients
Researchers evaluated the cost-utility of long-term, personalized exercise therapy compared to usual care in patients with axial spondyloart…
New research looks at whether personalized, long-term exercise programs are a cost-effective way to manage severe axial spondyloarthritis.
Jun 13, 2026
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Allergy & Immunology Sys. Review
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Frontiers Jun 4, 2026
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis
Allergy & Immunology Sys. Review
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis Stopping arthritis drugs before surgery may raise flare risk
This living systematic review evaluates perioperative management of conventional synthetic DMARDs in adults with rheumatoid arthritis, psori…
Low-certainty evidence suggests stopping certain arthritis drugs before surgery might increase the chance of a disease flare, but infection …
Cochrane May 20, 2026
Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks
Rheumatology RCT
Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks New Drug Offers Hope for Ankylosing Spondylitis Patients
This randomized, double-blind, placebo-controlled phase 2 to 3 trial included 548 adults with active r-axSpA in China. At week 16, the vunak…
If you live with the daily stiffness and pain of ankylosing spondylitis, a new treatment option may be on the horizon that works better than…
May 8, 2026
Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis and axial spondyloarthritis
Rheumatology Meta-analysis
Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis and axial spondyloarthritis New Gene Links Found Between Two Major Joint Diseases
This meta-analysis synthesizes data from three large European cohorts to identify new overlapping and disease-specific genetic risk factors …
This study reveals how specific genes may drive both shared and unique features of two common joint diseases, opening doors for more persona…
Frontiers Apr 24, 2026